Partner Headlines - TEVA

  1. Teva to pay $1.2 bil to settle

    IBD
  2. Regeneron, Lannett Among The 4 Top-Rated Drug Stocks

    IBD
  3. Benzinga's M&A Chatter for Wednesday May 27, 2015

    Benzinga
  4. TEVA PHARMA

    IBD
  5. Actavis Stock - A Must Have For Long-Term Investors

    GuruFocus
  6. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  7. Stanley Druckenmiller's Top 5 New Stocks

    GuruFocus
  8. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  9. Endo Buying Par Pharma To Become Top Generics Player

    IBD
  10. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  11. U.S. Loves Europe As Pharma, Energy Boost M&A

    IBD
  12. Actavis Offers Post-Allergan Guidance; Ligand Jumps

    IBD
  13. Actavis Q1 Beats Estimates, Includes Allergan In 2015 Guidance

    IBD
  14. Benzinga's Weekend M&A Chatter

    Benzinga
  15. Report: Mylan Might See Higher Bid From Teva

    Benzinga
  16. Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015

    Benzinga
  17. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  18. Leading Stock Mallinckrodt Delivers Strong Results As Base Forms

    IBD
  19. Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat

    IBD
  20. Report Sees 'Cognitive Dissonance' In Mylan's Internal Price ...

    Benzinga
  21. M&A Fever Grips Drugmakers

    IBD
  22. Is The Drug Industry's Wedding Dance Nearly Finished?

    IBD
  23. Gilead's Strong Profit Tops Mixed Drug maker Reports

    IBD
  24. Teva tops as it tries for Mylan

    IBD
  25. Teva, Celgene, Novo Nordisk, Shire Report Q1 Earnings

    IBD
  26. Teva Beats Q1 Estimates, Raises Full-Year Forecast

    Benzinga
  27. Mylan Raises Perrigo Bid, But Perrigo Still Says No

    IBD
  28. Benzinga's M&A Chatter for Monday April 27, 2015

    Benzinga
  29. Mylan Rejects 'Low Quality'

    IBD
  30. Nasdaq Leads Market Lower As Medical Stocks Tumble

    IBD
  31. 4 Drug Giants Reporting Earnings This Week

    IBD
  32. Mylan Rejects Teva Bid After Raising Bid For Perrigo

    IBD
  33. Teva Puts Forth Its Best Bid To Acquire Mylan

    GuruFocus
  34. Perrigo rebuffs Mylan again

    IBD
  35. Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds

    IBD
  36. Benzinga's M&A Chatter for Wednesday April 22, 2015

    Benzinga
  37. Teva Files for Hart-Scott-Rodino Notification Regarding Proposed ...

    Benzinga
  38. Teva Offers $40 Bil For Mylan; Perrigo Rejects Mylan

    IBD
  39. Teva Offers, Perrigo Rejects

    IBD
  40. Stocks End Mixed As Technology Sector Leads

    IBD
  41. Buyers Prop Up Nasdaq; Chipotle Rises Ahead Of Earnings

    IBD
  42. Stocks Mixed, But Palo Alto Hits High On Analyst Nod

    IBD
  43. Teva Bids $40 Billion For Mylan, But May Need More

    IBD
  44. Benzinga's Volume Movers

    Benzinga
  45. Mylan Shares Jump On $40 Billion Bid From Teva Pharmaceutical

    Benzinga
  46. Stocks Slip Into Mixed Trade; DuPont, Harley-Davidson Dive

    IBD
  47. Teva Offers $82 A Share For Mylan; Stocks Rise

    IBD
  48. Stock Futures Mildly Positive; Mylan, Fortinet, Mellanox Surge

    IBD
  49. Teva Pharmaceutical

    IBD
  50. Benzinga's Weekend M&A Chatter

    Benzinga
  51. Mylan

    IBD
  52. Global Worries Sink U.S. Stocks; Apple Breaches Support Level

    IBD
  53. Teva Getting Serious About Mylan Bid, Says Report

    IBD
  54. 8 IBD 50 Stocks Bucking The Market Sell-Off

    IBD
  55. Mylan: There's No Logic In The Teva Merger Rumor

    Benzinga
  56. Stocks Bleed Some More; Nasdaq Breaches Support Level

    IBD
  57. Mylan Scores Final Win In Patent Challenge On Inhalation Drug

    Benzinga
  58. Momenta, Novartis get FDA OK

    IBD
  59. Momenta, Novartis Win FDA Nod For Generic Copaxone

    IBD
  60. Insys Therapeutics Q4 beats

    IBD
  61. Insys Therapeutics Q4 Beat Drives Short-Lived Rally

    IBD
  62. Teva Announces Positive Results for TEV-48125 in Phase IIb Chronic ...

    Benzinga
  63. Stocks Hitting 52-Week Highs

    Benzinga
  64. Morning Market Gainers

    Benzinga
  65. Three Reasons To Let Akorn Fall Into Your Portfolio

    IBD
  66. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  67. Stocks Rise In Weak Trade; LinkedIn Jumps After Hours

    IBD
  68. Stocks Close Near Session Highs, But Volume Softens

    IBD
  69. Opko Health And Teva Pharmaceutical Industries Surge Following ...

    Benzinga
  70. Analysts are Bullish on IntelliPharmaceuticals Following Deal ...

    GuruFocus
  71. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  72. Deutsche Bank Offers Quick Thoughts On Teva Pharmaceutical's ...

    Benzinga
  73. Benzinga's Weekend M&A Chatter

    Benzinga
  74. Teva Pharmaceutical

    IBD
  75. Sterne Agee Analyst: Court Win To Boost Net At Teva Pharmaceutical

    Benzinga
  76. Jefferies Weighs In On Specialty Pharmaceuticals After Management ...

    Benzinga
  77. US Stock Futures Slip Ahead Of Home Price, Consumer Confidence ...

    Benzinga
  78. OncoGenex to Regain Rights to Custirsen from Teva

    Benzinga
  79. United Therapeutics: Will It Pass Peers In 2015?

    IBD
  80. Teva Upgraded On Strength Of Copaxone MS Drug

    IBD
  81. UPDATE: Sterne Agee Upgrades Teva Pharmaceutical

    Benzinga
  82. Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic ...

    Benzinga
  83. Merck-Cubist Deal Going Ahead Despite Patent Setback

    IBD
  84. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
  85. Why Opko Health Is a Better Investment Than Apple

    GuruFocus
  86. Benzinga's M&A Chatter for Tuesday November 18, 2014

    Benzinga
  87. Here Are The Top 25 Analysts On Wall Street

    Benzinga
  88. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  89. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close ...

    Benzinga
  90. Teva ups full-year EPS outlook

    IBD
  91. UPDATE: Teva Posts Stronger-Than-Expected Q3 Profit, Lifts Forecast

    Benzinga
  92. Earnings Scheduled For October 30, 2014

    Benzinga
  93. Lannett Co. Gets Growth Rx In Generic Drugs Group

    IBD
  94. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  95. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  96. Drugmaker M&A Goes On, With Or Without Tax Inversions

    IBD
  97. Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

    IBD
  98. Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects ...

    Benzinga
  99. Fast Money Halftime Report Final Trade From October 2 - Twitter ...

    Benzinga
  100. Insys Therapeutics Up On Bullish Analyst Initiation

    IBD
Trading Center